Vanderbilt Vaccine Center
-
Collector instincts and abstract thinking are behind immunologist James Crowe’s drive to use game-changing technology to prevent infectious disease
See how art collector turned immunologist James Crowe combines abstract thinking with game-changing technology to prevent infectious disease. Read MoreFeb 12, 2025
-
Study finds Moderna’s COVID-19 vaccine safe and effective for young children
A Vanderbilt study finds that Moderna’s COVID-19 vaccine is safe and effective in children 6 months to 5 years of age. Read MoreNov 4, 2022
-
Therapeutic antibodies for hantavirus
Vanderbilt Vaccine Center researchers have isolated monoclonal antibodies against hantaviruses, an emerging source of human disease with pandemic potential. Read MoreMay 24, 2021
-
Novel way to neutralize Rift Valley Fever Virus
The discovery of monoclonal antibodies that neutralize Rift Valley Fever Virus — an emerging infection with pandemic potential — lays the foundation for future therapeutic antibody development. Read MoreApr 1, 2021
-
Study shows new COVID target could improve vaccines
Despite an impressive vaccination effort that exceeds 2 million shots a day, rates of COVID-19 are again on the rise in several parts of the United States, as is the spread of highly transmissible variants of the virus. Read MoreApr 1, 2021
-
Shot in the Arm: Groundbreaking COVID-19 vaccine research by alumnus Dr. Barney Graham began at Vanderbilt decades ago
The remarkable success of the COVID-19 vaccines began in a Vanderbilt lab decades ago, with the groundbreaking research of alumnus Dr. Barney Graham. Read MoreMar 17, 2021
-
Exploiting viral vulnerabilities
The isolation of human monoclonal antibodies against dangerous viruses including EEEV, Hendra and Nipah could offer new ways to treat and prevent these infections. Read MoreDec 10, 2020
-
Vanderbilt University Medical Center’s Crowe receives 2020 “Golden Goose” Award for COVID-19 research
James Crowe Jr., MD, a physician-scientist at Vanderbilt University Medical Center who has pioneered development of human monoclonal antibodies as potential treatments for viral diseases, has won a 2020 “Golden Goose” Award. Read MoreDec 1, 2020
-
Antibody research at Vanderbilt University Medical Center shows promise in fight against COVID-19
Based on positive results in preclinical studies reported today, potently neutralizing antibodies identified by researchers at Vanderbilt University Medical Center are showing promise as a potential therapy for preventing and treating COVID-19. Read MoreJul 15, 2020
-
Research team isolates antibodies that may prevent rare polio-like illness in children linked to a respiratory infection
Researchers at Vanderbilt University Medical Center, Purdue University and the University of Wisconsin-Madison have isolated human monoclonal antibodies that potentially can prevent a rare but devastating polio-like illness in children linked to a respiratory viral infection. Read MoreJul 3, 2020
-
The Front Lines: Vanderbilt physicians, researchers join worldwide fight against COVID-19
From the front lines of patient care to collaborating with scientists across the globe searching for treatments and vaccines, Vanderbilt University Medical Center and Vanderbilt University researchers have been working for months to combat the COVID-19 pandemic. Read MoreMay 14, 2020
-
Antibodies eye Pacific Island “fever”
Vanderbilt Vaccine Center team isolates monoclonal antibodies against the mosquito-borne Ross River virus, which causes rash, fever and debilitating muscle and joint pain lasting three to six months. Read MoreMay 14, 2020
-
Antibody finding raises hopes for Marburg, COVID-19 treatments
Monoclonal antibodies against Marburg virus — a more lethal cousin of the RNA virus that causes COVID-19 — may aid in the development of antibody "cocktails" to counter viral infection. Read MoreApr 30, 2020
-
Antibody mixture may help block Ebola virus infection
A research team led by scientists at Vanderbilt University Medical Center has developed an antibody mixture that in animals is highly effective in blocking infection by the Ebola virus. Read MoreFeb 6, 2020
-
VUMC-led team isolates antibody that blocks bird flu
VUMC scientists are redoubling their efforts to help people fight off bird flu. Their focus is H7N9, one of the most dangerous of the influenza viruses that have been transmitted from birds to humans. Read MoreDec 12, 2019
-
New tool may speed antibody, vaccine research
Antibody discovery and vaccine development research may be on the verge of rapidly expanding with data that previously took decades to acquire, thanks to LIBRA-seq, a new tool developed by Vanderbilt University researchers and their colleagues. Read MoreDec 12, 2019
-
Partnership to help bring Zika virus therapy to clinic
Researchers at Vanderbilt University Medical Center are partnering with the Dutch biopharmaceutical firm Batavia Biosciences and Nashville-based IDBiologics to bring to the clinic a highly potent Zika virus neutralizing antibody they isolated three years ago. Read MoreSep 4, 2019
-
Vanderbilt vaccine pioneer James Crowe honored with major science prize
James Crowe Jr., MD, director of the Vanderbilt Vaccine Center, will be honored today by the science and technology company Merck KGaA, Darmstadt, Germany for his contributions to developing new therapeutics and vaccines against some of the world’s deadliest viruses. Read MoreJul 9, 2019
-
New method tested to block chikungunya infection
Scientists are testing a new way to fight chikungunya virus that involves injecting genetic material into the bodies of infected and at-risk individuals to trigger rapid production of potent, virus-neutralizing antibodies. Read MoreJun 14, 2019
-
VUMC joins international effort to speed vaccine development
VUMC has joined an international effort to streamline and accelerate development of vaccines and other treatments against a growing worldwide surge of deadly and debilitating viral infections. Read MoreJun 6, 2019